AUTHORS
Guy Young, MD, Cédric Hermans2, Manuel Carcao, MD3, Hervé Chambost4, Julie Curtin, PhD, MBBS, FRACP, FRCPA5, Martin Olivieri, MD6, Sheng-Chieh Chou, MD7, Elena Santagostino, MD, PhD8, Graham Neill, PhD9, Meredith C. Foster10, Linda Bystrická11, Sriya Gunawardena12, Flora Peyvandi13
AFFILIATIONS
1 Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United States
2 Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium
3 Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
4 Department of Pediatric Hematology Oncology, AP-HM, Children Hospital La Timone & Aix Marseille University, INSERM, INRA, C2VN, Marseille, France
5 Department of Haematology, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
6 Pediatric Thrombosis and Haemostasis Unit, Paediatric Haemophilia Center, Dr. von Hauner Children’s Hospital, LMU Munich, Munich, Germany
7 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
8 Sobi, Basel, Switzerland
9 Sanofi, Cambridge, United Kingdom
10 Sanofi, Cambridge, Massachusetts, United States
11 Sobi, Basel, Switzerland
12 Sanofi, Morristown, New Jersey, United States
13 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
ABSTRACT
Background
Achieving zero or near-zero bleeding episodes represents a critical therapeutic goal in severe hemophilia A, with implications for joint preservation and quality-of-life improvement. Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy, also referred to as ultralong half-life FVIII, which has demonstrated high efficacy in the XTEND clinical program. Here, we present data on treated bleed rates over a 3-year period of efanesoctocog prophylaxis (once-weekly 50 IU/kg) in XTEND-ed since parent study baseline in patients with at least 156 weeks of treatment.
Methods
This interim analysis (data cut 21 February 2025) included the subset of XTEND-ed patients who completed either XTEND-1 or XTEND-Kids and continued into XTEND-ed Arm A and had at least 156 weeks (3 years) of cumulative treatment with efanesoctocog alfa since their first prophylactic dose in the parent study. Age cohorts were <12 years vs ≥12 years at the time of enrollment in the parent study. Baseline demographics were summarized for included patients. Outcomes of interest included number of treated bleeds, percentage of patients with zero treated bleeds (overall and by 6-month intervals), annualized bleeding rate (ABR) for treated bleeds, and bleeding patterns by type and location. Bleeds could be reported in multiple locations; multiple locations treated with a single injection were considered a single bleeding episode. All outcomes were analyzed during the first 156 weeks of treatment.
Results
Overall, 179 out of 217 (82%) patients from XTEND-ed had at least 156 weeks of treatment duration since their first prophylactic dose in XTEND-1 or XTEND-Kids; 73% (131/179) were ≥12 years and 27% (48/179) of patients were age ≤12 years at parent study baseline. All patients except 1 were male.
During the 156-week period, 368 treated bleeds were reported in 108 patients including 109 spontaneous bleeds and 189 traumatic bleeds. The mean (SD) and median (Q1; Q3) number of bleeding episodes per patient were 2.06 (3.14) and 1.0 (0.00; 3.00), respectively. Regarding bleed type, the mean (SD) number of spontaneous and traumatic bleeding episodes were 0.61 (1.12) and 1.06 (1.76) per patient, respectively. For the whole cohort, the mean (95% CI) model-based ABR was 0.70 (0.56; 0.86); 0.79 (0.53; 1.18) for <12 years and 0.66 (0.52; 0.85) for ≥12 years. Median (Q1; Q3) ABR values for overall, <12 years, and ≥12 years were 0.34 (0.00; 1.00), 0.51 (0.00; 1.18), and 0.34 (0.00; 0.72), respectively. Among the 108 patients with treated bleeds, the 3 most common bleed locations were joints (89/108, 82%), muscles (33/108, 31%), and skin or mucosa (29/108, 27%).
Over the full 3-year period, 40% percent (71/179) of patients experienced zero bleeds, 68% (122/179) experienced zero spontaneous bleeds, and 55% (98/179) experienced zero traumatic bleeds. Forty percent (72/179) of patients experienced 1 to 3 bleeds. No patient <12 years experienced >3 spontaneous bleeds, and no patient ≥12 years experienced >5 spontaneous bleeds. Zero bleed rates ranged from 75% to 79% per 6-month intervals.
Conclusions
These data demonstrate the high sustained efficacy of efanesoctocog alfa due to persistent zero or near-zero bleed rates. Over the 3-year period, patients reported a median of 1 bleed with 40% of patients reporting no bleeds and 68% reporting no spontaneous bleeds, thus highlighting the potential for improved long-term clinical outcomes in patients with severe hemophilia A.
DISCLOSURES
Guy Young, MD: Novo Nordisk - Honoraria; HEMA Biologics/LFB - Honoraria; Genentech/Roche - Honoraria; BioMarin - Honoraria; Spark - Honoraria; Pfizer - Honoraria; Sanofi - Honoraria; Sanofi - Research Funding; Pfizer - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Spark - Consultancy (Includes expert testimony); HEMA Biologics/LFB - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony)